Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Ergonomic Training With or Without Structured Exercise in Oil Industry Workers With Chronic Musculoskeletal Pain

11 novembre 2026 aggiornato da: Doç.Dr.Ömer Şevgin, Uskudar University

Effect of Structured Exercise Added to Ergonomic Training on Pain, Pain-Related Disability and Quality of Life in Oil Industry Workers With Chronic Musculoskeletal Disorders: A Randomized Controlled Trial

This randomized controlled trial will investigate whether a 12-week structured exercise program added to ergonomic training reduces pain and pain-related disability and improves quality of life more than ergonomic training alone in oil industry workers with chronic musculoskeletal pain. Forty workers aged 25-50 years with musculoskeletal pain lasting at least 3 months will be randomly assigned to either ergonomic training plus exercise or ergonomic training only. Both groups will receive two 45-minute ergonomic training sessions specific to oil-field work (weeks 1 and 6) and a printed brochure. The exercise group will additionally perform a phased neuromuscular and resistance exercise program 3 days per week for 12 weeks, partly supervised at the worksite and partly home/worksite-based. Pain intensity (visual analogue scale), pain-related disability (Pain Disability Index), quality of life (SF-12), regional musculoskeletal symptoms (Extended Nordic Musculoskeletal Questionnaire) and sleep quality (Pittsburgh Sleep Quality Index) will be assessed by an assessor blinded to group allocation at baseline and after 12 weeks.

Panoramica dello studio

Descrizione dettagliata

Background: Work-related musculoskeletal disorders are a leading cause of lost productivity and disability. Oil and gas installations combine heavy lifting, repetitive work, awkward postures, vibrating tools, prolonged standing and shift work; musculoskeletal symptom prevalence of 71-89% has been reported in this workforce. Multicomponent workplace programs combining exercise, ergonomics and education provide the most consistent benefit for pain and function, and ergonomic-educational interventions alone have reduced symptoms in oil and gas workers; however, no randomized controlled trial has evaluated the added value of exercise in this population.

Design: Prospective, assessor-blinded, two-arm, parallel-group, 1:1 randomized controlled trial conducted at a single oil industry facility. The study will be reported according to CONSORT and TIDieR. Participants will be randomized using a computer-generated list with variable block sizes (4 and 6); allocation will be concealed in sequentially numbered, opaque, sealed envelopes prepared by an investigator not involved in treatment or assessment.

Interventions: Both groups receive ergonomic training specific to oil-field work: two 45-minute face-to-face group sessions (8-12 workers) at weeks 1 and 6 covering musculoskeletal risk factors, NIOSH lifting principles, valve/flange and overhead work, hand-arm and whole-body vibration, prolonged standing and grated floors, control-room/office ergonomics, shift work and sleep hygiene, and a 5-minute micro-break routine, plus a printed brochure and micro-break card, with weekly reminder messages for 12 weeks. The exercise group additionally performs a 12-week structured program, 3 non-consecutive days per week, 45 minutes per session (36 sessions): weeks 1-2 fully supervised at the facility in groups of 4-6, weeks 3-12 one supervised and two home/worksite-based sessions per week supported by an illustrated brochure and guided video. Each session comprises warm-up and mobility (6 min), neuromuscular stabilization (12 min), resistance strengthening with elastic bands and light loads (14 min), job-specific functional exercise such as box lifting and carrying (6 min) and stretching (7 min). The program progresses through three phases (motor control and activation, weeks 1-4; endurance and strength, weeks 5-8; job-specific functional loading, weeks 9-12) with intensity targeted at Borg CR-10 4-6 and load progression by the 2-for-2 rule. The control group receives weekly ergonomic reminder messages and a telephone call every 2 weeks to equalize contact; the exercise program is offered to the control group after final assessment.

Outcomes: Assessments at baseline (T0) and at the end of the 12-week intervention (T1) by a physiotherapist blinded to group allocation. Primary outcome: pain intensity on a 0-10 cm visual analogue scale. Secondary outcomes: Pain Disability Index (0-70), SF-12 physical and mental component summaries, regional symptom prevalence on the Extended Nordic Musculoskeletal Questionnaire, and sleep quality on the Pittsburgh Sleep Quality Index (exploratory). Process measures: session adherence, Borg CR-10 and adverse events.

Sample size: A priori power analysis (G*Power 3.1; repeated-measures ANOVA, within-between interaction; f = 0.25, alpha = 0.05, power = 0.80, 2 groups, 2 measurements, correlation 0.50) indicated 34 participants; allowing for 15-20% attrition, 40 participants (20 per group) will be enrolled.

Analysis: Intention-to-treat with multiple imputation; per-protocol (adherence ≥70%) as sensitivity analysis. Primary outcome analyzed with 2 × 2 mixed-design repeated-measures ANOVA (group × time interaction) or ANCOVA on the week-12 score adjusted for baseline. Secondary continuous outcomes analyzed in the same way; Benjamini-Hochberg correction for secondary outcomes. Dichotomous Nordic data analyzed with McNemar and chi-square/Fisher tests. Effect sizes (partial eta squared, Cohen d) with 95% CIs, proportion exceeding the minimal clinically important difference and number needed to treat will be reported. Significance p < 0.05.

Tipo di studio

Interventistico

Iscrizione (Stimato)

40

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 25 anni a 50 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age 25-50 years
  • Employed in the oil industry for at least 5 years
  • Musculoskeletal pain lasting at least 3 months, with symptoms in at least one body region in the last 12 months and the last 7 days on the Nordic Musculoskeletal Questionnaire
  • Pain intensity ≥3/10 on the visual analogue scale
  • Literate and able to communicate
  • Willing to participate and signing the informed consent form

Exclusion Criteria:

  • Spinal or extremity surgery or trauma within the last 6 months
  • Inflammatory rheumatic disease, radicular neurological signs (motor or reflex loss) or history of malignancy
  • Uncontrolled cardiovascular, pulmonary or neurological disease precluding exercise
  • Pregnancy
  • Physiotherapy/rehabilitation within the last 3 months or regular structured exercise ≥150 minutes per week
  • Planned job change or relocation during the study period

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Ergonomic training + structured exercise

Oil-field-specific ergonomic training (two 45-min sessions at weeks 1 and 6, brochure, weekly reminders) plus a 12-week phased neuromuscular and resistance exercise program, 3 days/week, 45 min/session, partly supervised at the worksite.

12 weeks, 3 non-consecutive days/week, 45 min/session (36 sessions). Weeks 1-2 fully supervised by a physiotherapist at the facility (groups of 4-6); weeks 3-12 one supervised + two home/worksite-based sessions per week with illustrated brochure and guided video. Three phases: motor control/activation (weeks 1-4, body weight and light bands), endurance/strength (weeks 5-8, medium bands, 5-8 kg), job-specific functional loading (weeks 9-12, heavy bands, 8-12 kg). Intensity Borg CR-10 4-6; progression by 2-for-2 rule; pain rule ≤3/10 during exercise returning to baseline within 24 h.

Comparatore attivo: Ergonomic training only (active control)

The same oil-field-specific ergonomic training (two 45-min sessions at weeks 1 and 6, brochure, weekly reminders) and a telephone call every 2 weeks for contact equalization; no exercise program during the study. The exercise program is offered after final assessment.

12 weeks, 3 non-consecutive days/week, 45 min/session (36 sessions). Weeks 1-2 fully supervised by a physiotherapist at the facility (groups of 4-6); weeks 3-12 one supervised + two home/worksite-based sessions per week with illustrated brochure and guided video. Three phases: motor control/activation (weeks 1-4, body weight and light bands), endurance/strength (weeks 5-8, medium bands, 5-8 kg), job-specific functional loading (weeks 9-12, heavy bands, 8-12 kg). Intensity Borg CR-10 4-6; progression by 2-for-2 rule; pain rule ≤3/10 during exercise returning to baseline within 24 h.

Two 45-minute face-to-face group sessions (8-12 workers) at weeks 1 and 6 delivered by a physiotherapist (short presentation, practical demonstration and teach-back, discussion). Content: oil-field musculoskeletal risk factors; NIOSH lifting principles; valve/flange and overhead work; vibrating tools and hand-arm vibration; prolonged standing, grated floors and stairs; vehicle/cabin and whole-body vibration; control-room/office ergonomics; shift schedules and sleep hygiene; 5-minute micro-break routine. Printed brochure and micro-break card; weekly reminder messages for 12 weeks.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in pain intensity (Visual Analogue Scale)
Lasso di tempo: Baseline, Week 12

Average pain over the past week marked on a 10 cm horizontal line (0 = no pain, 10 = worst imaginable pain), measured in cm. Lower scores indicate less pain. Minimal clinically important difference ≥2 cm or ≥30%.

Baseline, Week 12

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in pain-related disability (Pain Disability Index)
Lasso di tempo: Baseline, Week 12

7 items (family/home responsibilities, recreation, social activity, occupation, sexual behavior, self-care, life-support activity) each rated 0-10; total 0-70, higher scores indicate greater disability. Turkish version validated.

Baseline, Week 12
Change in health-related quality of life (SF-12)
Lasso di tempo: Baseline, Week 12

Physical Component Summary (PCS) and Mental Component Summary (MCS) scores, each 0-100; higher scores indicate better quality of life. Turkish version validated.

Baseline, Week 12
Change in regional musculoskeletal symptom prevalence (Extended Nordic Musculoskeletal Questionnaire)
Lasso di tempo: Baseline, Week 12

Presence of symptoms (yes/no) in the last 7 days and last 12 months and activity limitation in nine body regions (neck, shoulders, upper back, lower back, elbows, wrists/hands, hips/thighs, knees, ankles/feet). Turkish version validated.

Baseline, Week 12
Change in sleep quality (Pittsburgh Sleep Quality Index) - exploratory
Lasso di tempo: Baseline, Week 12

Seven component scores (0-3) summed to a global score 0-21; scores >5 indicate poor sleep quality. Turkish version validated.

Baseline, Week 12

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Cattedra di studio: Sedat Kartal, Üsküdar University

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

15 dicembre 2026

Completamento primario (Stimato)

20 maggio 2027

Completamento dello studio (Stimato)

20 maggio 2027

Date di iscrizione allo studio

Primo inviato

11 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

11 novembre 2026

Primo Inserito (Effettivo)

17 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Descrizione del piano IPD

De-identified individual participant data may be made available from the principal investigator upon reasonable request after publication of the main results.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi